Healthcare sector | Medical Instruments & Supplies industry
| Price | $3.15 |
|---|---|
| Shares Outstanding | 71.73M |
| All-Time Low | $1.79 |
| 52-Week Low | $2.08 |
| Net Cash / Share | $2.17 |
|---|---|
| Net Current Assets / Share | $3.09 |
| Net Tangible Assets / Share | $4.23 |
| Shares Outstanding Ave Change (Annual) | 1.16% |
| Shares Δ YoY | 1.46% |
| Avg CA Burn (Annual %) | 4.57% (as of 2-20-2026) |
| Avg CA Burn (Quarterly %) | -5.18% (as of 2-20-2026) |
| Max Earning Power / Share | $-1.77 |
|---|---|
| Adjusted Earning Power |
$-1.82
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
1.06%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 18.9M (as of 2-20-2026) |
| Avg EBITDA (5Q) | 0 (as of 2-20-2026) |
| Avg Net Income (5Y) | -1.5M (as of 2-20-2026) |
| Avg Net Income (5Q) | -12.9M (as of 2-20-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 2-20-2026 |
| Consecutive Years Paid | No | 2-20-2026 |
| Pays Dividend | No | 2-20-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 2-20-2026 |
| Net Income Positive | No | 2-20-2026 |
| Current Dividend Streak | No | 2-20-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 5 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-09-30 | Quarterly | $4.20 | 303.5M ($303,465,000) | 72.3M (72,265,000) |
| 2025-06-30 | Quarterly | $4.36 | 321.7M ($321,710,000) | 73.7M (73,735,000) |
| 2025-03-31 | Quarterly | $4.51 | 338.5M ($338,526,000) | 75.1M (75,114,000) |
| 2024-12-31 | Quarterly | $4.73 | 352.6M ($352,573,000) | 74.6M (74,598,000) |
| 2024-12-31 | Annual | $4.73 | 352.6M ($352,573,000) | 74.6M (74,598,000) |
| 2024-09-30 | Quarterly | $5.22 | 389.6M ($389,613,000) | 74.6M (74,593,000) |
| 2023-12-31 | Annual | $5.36 | 393.8M ($393,769,000) | 73.5M (73,528,000) |
| 2022-12-31 | Annual | $4.37 | 317.6M ($317,627,000) | 72.7M (72,734,000) |
| 2021-12-31 | Annual | $4.52 | 325.9M ($325,911,000) | 72.1M (72,069,000) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 185.8M ($185,827,000) |
| 2023-12-31 | 405.5M ($405,472,000) |
| 2022-12-31 | 387.5M ($387,479,000) |
| 2021-12-31 | 233.7M ($233,674,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| 1998-01-08 | $1.6 |
| Date | Shares Outstanding | Delta |
|---|---|---|
| No recent share changes | ||
Latest short-interest change: 4,020,489 shares (5.74% of float) | Days to cover: 8.07
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-02-27 | 4,020,489 shares | +134,296 | +3.46% |
| 2026-02-11 | 3,886,193 shares | -72,513 | -1.83% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.